Oncolytic virotherapy and the current approaches in veterinary medicine
-
Published:2022
Issue:2
Volume:2
Page:17-27
-
ISSN:2703-1322
-
Container-title:German Journal of Veterinary Research
-
language:en
-
Short-container-title:Ger. J. Vet. Res.
Author:
Bilgiç Bengü,Dokuzeylül Banu,Or Mehmet E.
Abstract
Cancer has an increasing incidence worldwide in humans and animals. In addition to traditional treatments such as surgery, radiotherapy, and chemotherapy, there is a search for new treatment strategies for cancer treatment. Oncolytic virotherapy arouses great interest in human medicine with the development of biotechnology and increasing knowledge about virus-cell interactions in recent years. Many in-vivo and in-vitro studies have led to the development of a United States Food and Drug Administration (FDA)-approved, genetically modified oncolytic viral therapy. Based on the studies in human medicine, some clinical trials have also been carried out with oncolytic virotherapy in veterinary medicine. But the studies in cats and dogs are very limited. This review aims to compare the development of oncolytic virotherapy in human and veterinary medicine with current studies and to draw attention to the fact that virotherapy can be used as a treatment option for various tumoral diseases in veterinary medicine in the future.
Publisher
German Multidisciplinary Publishing Center
Subject
Genetics,Animal Science and Zoology
Reference96 articles.
1. Adair, R.A., Roulstone, V., Scott, K.J., Morgan, R., Nuovo, G.J., Fuller, M., Beirne, D., West, E.J., Jennings, V.A., Rose, A., Kyula, J., Fraser, S., Dave, R., Anthoney, D.A., Merrick, A., Prestwich, R., Aldouri, A., Donnelly, O., Pandha, H., Coffey, M., Selby, P., Vile, R., Toogood, G., Harrington, K., Melcher, A.A., 2012. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci. Transl. Med. 4, 138ra77. doi:10.1126/scitranslmed.3003578 2. Aita, V.M., Liang, X.H., Murty, V.V., Pincus, D.L., Yu, W., Cayanis, E., Kalachikov, S., Gilliam, T.C., Levine, B., 1999. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 59, 59–65. doi:10.1006/geno.1999.5851 3. Alberts, P., Olmane, E., Brokāne, L., Krastiņa, Z., Romanovska, M., Kupčs, K., Isajevs, S., Proboka, G., Erdmanis, R., Nazarovs, J., Venskus, D., 2016. Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. APMIS 124, 896–904. doi:10.1111/apm.12576 4. Alberts, P., Tilgase, A., Rasa, A., Bandere, K., Venskus, D., 2018. The advent of oncolytic virotherapy in oncology: The Rigvir® story. Eur. J. Pharmacol. 837, 117–126. doi:10.1016/j.ejphar.2018.08.042 5. Alemany, R., Balagué, C., Curiel, D.T., 2000. Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18, 723–727. doi:10.1038/77283
|
|